- Mangoceuticals Inc. (MGRX, Financial) broadens its innovative health product range with telemedicine solutions.
- Company launches PeachesRx, a women's wellness brand, expanding beyond men's health.
- Exclusive distribution rights to Diabetinol® aim to enter the $33 billion diabetes market.
Mangoceuticals Inc. (NASDAQ:MGRX) is solidifying its footprint in the health and wellness sphere by introducing a suite of innovative products aimed at addressing a variety of health challenges for both men and women. Central to its offering is the unique Mango product line, which includes solutions for erectile dysfunction (ED) available in two formulations: Sildenafil Mango and Tadalafil Mango. Both versions feature fast-acting dissolvable tablets that are flavored and packaged discreetly, enhancing user experience and convenience.
The company's product portfolio also includes Prime by MangoRx, a telehealth-enabled testosterone replacement therapy using Kyzatrex™, an FDA-approved oral testosterone capsule. This approach eliminates the need for injections and clinics, offering a streamlined experience for users.
For those dealing with hair loss, Grow by MangoRx offers a comprehensive treatment combining Minoxidil, Finasteride, Biotin, and Vitamin D3, delivered in a mint-flavored chewable tablet. Meanwhile, Slim by MangoRx targets weight loss with an oral dissolving tablet containing Semaglutide, a proven compound in modern weight management.
In addition to these male-focused offerings, Mangoceuticals has launched PeachesRx, a women's wellness brand designed to expand their reach into the women's health market. This move positions the company to create a holistic wellness ecosystem.
Moreover, Mangoceuticals has secured exclusive US and Canadian distribution rights for Diabetinol®, a patented plant-based nutraceutical aimed at improving metabolic health, thus entering the expansive $33 billion diabetes market.
